Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

145 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
TIMI risk score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy.
Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, Giugliano RP, McCabe CH, Braunwald E. Morrow DA, et al. Among authors: charlesworth a. Circulation. 2000 Oct 24;102(17):2031-7. doi: 10.1161/01.cir.102.17.2031. Circulation. 2000. PMID: 11044416
Comparison of a 60- versus 90-minute determination of ST-segment resolution after thrombolytic therapy for acute myocardial infarction. In TIME-II Investigators. Intravenous nPA for Treatment of Infarcting Myocardium Early-II.
de Lemos JA, Antman EM, Giugliano RP, Morrow DA, McCabe CH, Cutler SS, Charlesworth A, Schröder R, Braunwald E. de Lemos JA, et al. Among authors: charlesworth a. Am J Cardiol. 2000 Dec 1;86(11):1235-7, A5. doi: 10.1016/s0002-9149(00)01207-8. Am J Cardiol. 2000. PMID: 11090796 Clinical Trial.
Geographic variation in patient and hospital characteristics, management, and clinical outcomes in ST-elevation myocardial infarction treated with fibrinolysis. Results from InTIME-II.
Giugliano RP, Llevadot J, Wilcox RG, Gurfinkel EP, McCabe CH, Charlesworth A, Thompson SL, Antman EM, Braunwald E; InTIME (Intravenous nPA for Treatment of Infarcting Myocardium Early) II Investigators. Giugliano RP, et al. Among authors: charlesworth a. Eur Heart J. 2001 Sep;22(18):1702-15. doi: 10.1053/euhj.2001.2583. Eur Heart J. 2001. PMID: 11511120 Clinical Trial.
Availability of on-site catheterization and clinical outcomes in patients receiving fibrinolysis for ST-elevation myocardial infarction.
Llevadot J, Giugliano RP, Antman EM, Wilcox RG, Gurfinkel EP, Henry T, McCabe CH, Charlesworth A, Thompson S, Nicolau JC, Tebbe U, Sadowski Z, Braunwald E; InTIME (Intravenous nPA for Treatment of Infarcting Myocardium Early) II Investigators. Llevadot J, et al. Among authors: charlesworth a. Eur Heart J. 2001 Nov;22(22):2104-15. doi: 10.1053/euhj.2001.2622. Eur Heart J. 2001. PMID: 11686667 Clinical Trial.
Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial.
Scirica BM, Cannon CP, Cooper R, Aster RH, Brassard J, McCabe CH, Charlesworth A, Skene AM, Braunwald E. Scirica BM, et al. Among authors: charlesworth a. J Thromb Thrombolysis. 2006 Oct;22(2):95-102. doi: 10.1007/s11239-006-8669-4. J Thromb Thrombolysis. 2006. PMID: 17008974 Clinical Trial.
Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study.
Cotter G, Cannon CP, McCabe CH, Michowitz Y, Kaluski E, Charlesworth A, Milo O, Bentley J, Blatt A, Krakover R, Zimlichman R, Reisin L, Marmor A, Lewis B, Vered Z, Caspi A, Braunwald E; OPUS-TIMI 16 Investigators. Cotter G, et al. Among authors: charlesworth a. Am Heart J. 2003 Apr;145(4):622-7. doi: 10.1067/mhj.2003.6. Am Heart J. 2003. PMID: 12679757 Clinical Trial.
145 results